Giulio M. Pasinetti

  • PROFESSOR Neurology
  • PROFESSOR Psychiatry
  • PROFESSOR Geriatrics and Palliative Medicine
  • PROFESSOR Neuroscience
Print ProfilePrint Profile

Education

  • Ph.D., University of Milan
    Pharmacology

  • M.D., University of Milan Medical School

Biography

    Dr. Giulio Maria Pasinetti is a Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine, New York. Dr. Pasinetti graduated from Milan University School of Medicine in 1982, and he received his Ph.D. from the University of Milan in 1988. He joined the Mount Sinai School of Medicine's faculty in 1996 and has consistently maintained an outstanding record of excellence and exceptional productivity.

    Dr. Pasinetti is a recipient of several academic awards including the prestigious Zenith and Temple awards from the Alzheimer's Association. Most recently, Dr. Pasinetti was awarded ''The Faculty Council Award'' for academic excellence at Mount Sinai School of Medicine and "The Charles Dana Alliance for Brain Research Award"  from Dana Foundation, recognizing productivity and the worldwide leadership in his field of expertise, which further emphasizes his standing as an academic role model.

    Learn more about Dr. Pasinetti's research connecting diabetes and Alzheimer's disease in Inside Mount Sinai.

    Dr. Pasinetti was also recently awarded with an NIH funded research grant supporting a ''Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease,'' of which he is the Principal Investigator and Director. The NIH funded Center is the first in the country exploring the potential beneficial role of natural grape -derived polyphenolic compounds implicated in mechanisms associated with the prevention of Alzheimer's disease (AD) neuropathology. Dr. Pasinetti also serves as the Director of the Basic and Biomedical Research and Training Program, GRECC James J. Peters Veterans Affairs Medical Center at the Bronx VA.

Awards

  • 2007 -
    Foundation Queen Sofia of Spain Research Center award on Alzheimer's Disease

  • 2005 -
    Faculty Council Award for Academic Excellence
    Mount Sinai School of Medicine

  • 2004 -
    Dana Alliance for Brain Initiatives Award

  • 2003 -
    Zenith Award from Alzheimer's Association

  • 2000 -
    Temple Foundation Discovery Award from Alzheimer's Association

  • 1994 -
    Nathan W. & Margaret T. Shock Aging Research Foundation Award of the Gerontology Society of America

  • 1991 -
    Turken Family fellowship from Alzheimer's Association
    Los Angeles Chapter

  • 1991 -
    Nathan Shock New Investigator Award of the Gerontology Society of America

Research

Specific Clinical/Research Interest:
Neuronal Degeneration in Alzheimer's Disease and Model System

Postdoctoral Fellows: Xianjuan Qian, PhD, Shrishailam Yemul, PhD, Wei Zhao, PhD; Carmen Diaz, PhD; Isabel Arrieta-Cruz, PhD

Research Personnel: Faculty: Lap Ho, PhD, Hanna Reding, PhD, Jun Wang, PhD., Yong Pan, PhD, Bing Gong, PhD

Summary of Research Studies:
The primary research goals in Dr. Pasinetti's lab is to investigate the biological processes which occur when, during aging, subjects with normal cognitive functions convert into the very earliest stages of Alzheimer's disease (AD) and then to frank dementia. The long-term goal of Dr. Pasinetti's lab is to improve the diagnosis of patients who are in the very earliest stages of Alzheimer's disease (AD), and to identify early molecular neurobiological abnormalities so that effective pharmacological treatments to slow or halt disease progression can be developed. Toward this goal Dr. Pasinetti's lab initiated a series of studies to characterize gene activities in the brain of early AD cases and animal model system of AD neuropathology, using high throughput cDNA and microarray approaches. Recent studies in Dr. Pasinetti's lab found that the expression of genes involved in synaptic functions, cell cycle, and cytoskeleton/cell adhesion, may play an important role in the onset and possibly the clinical progression of Alzheimer's disease dementia. More recently, Dr. Pasinetti's lab using a combination of genomic-proteomic techniques is presently characterizing and purifying abnormal expressed gene products in the brain that may share similarities in respect with promotion of neurodegenerative disorders including amyotrophic lateral sclerosis and Parkinson's disease among others. Based on the outcome of these studies, Dr Pasinetti's lab is presently using newly developed transgenic mouse models of disease to test pre-clinically the potential therapeutic relevance of novel drug treatments. 

Publications

Ferruzzi MG, Lobo JK, Janle EM, Whittaker N, Cooper B, Simon JE, Wu Q, Welch C, Ho L, Weaver C, Pasinetti GM. Brain bioavailability of gallic acid and catechins is improved by repeated dosing in rats: Implications for treatment in Alzheimer's disease. Mol Nutr Food Res 2009, under review;.

Qin W, Haroutunian V, Katsel P, Cardozo C, Ho L, Buxbaum JD, Puigserver P, Pasinetti GM. PGC-1alpha expression decreases in the brain of Alzheimer's disease as a function of progression of clinical dementia. Arch Neurol 2008;: in press.

Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimer's disease biomarker with anti-amyloidogenic activities acts via selective promotion of ADAM-10. PLoS ONE 2009;: in press.

Zhao W, Wang J, Ho L, Teplow D, Pasinetti GM. Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alz Dis 2009;: in press.

Ho L, Yemul S, Wang J, Pasinetti GM. Grape seed polyphenolic extract (GSE) as a novel therapeutic agent in tauopathies. J Alzheimer's Dis 2009;: in press.

Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Dickstein DL, Pasinetti GM. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neurophathology and cognitive deterioration. J Alz Dis 2009;: in press.

Pfleger CM, Friendman L, Vittorino R, Conley LM, Ho L, Pasinetti GM. Grape Seed Polyphenolic (GSPE) as a potential novel therapeutic agent in neurodegenerative disorders characterized by misfolded/abnormally aggregated proteins in the brain. Neurobiol of Aging 2009;: in press.

Ono K, Condron MM, Ho G, Wang J, Zhao W, Pasinetti GM. Effects of Grape Seed-Derived Polyphenols on Amyloid B-Protein Self-Assembly and Cytotoxicity. Journal Biological Chemistry 2008; 283(47): 32176-32187.

Wang , Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci 2008; 18: 6388-6392.

Wang J, Ho L, Chen L, Zhao Z, Zhao W, Humala N, Seror I, Bartholomew S, Land D, Galvez J, Rosendorff C, Pasinetti GM. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Investigation 2007; 117(11): 3393-3402.

Industry Relationships

Physicians and scientists on the faculty of Mount Sinai School of Medicine often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Pasinetti did not report having any of the following types of financial relationships with industry during 2011 and/or 2012: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://www.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Annenberg Building Floor Annenberg 20 Room -06
1468 Madison Avenue
New York, NY 10029


Address

Annenberg Building Room 14-94C (Lab)
1468 Madison Avenue
New York, NY 10029

Tel: 212-254-1592

Address

Annenberg Building Floor 2 Room 24
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-7938